Eighty-eight percent of respondents reported having health insurance, while 12% said they did not
Each increase brings changes, both in results and in how the medication feels
While a promising strategy, LUNAR, a phase III placebo-controlled trial using rituximab as an add-on therapy, did not achieve its primary endpoints of a complete or partial renal response at 52 weeks (Rovin et al, Arthritis Rheum 2012)
The Pro version is typically distributed through healthcare providers and specialty pharmacies, and it shares the same core formulation but is positioned for clinical recommendations
It can reduce the risk of hyperglycemia and its associated complications
Eli Lilly, the maker of tirzepatide, recently published results of a head-to-head trial comparing weight loss of Zepbound (tirzepatide) and Wegovy (semaglutide)